HHS' Thompson Clarifies RU-486 Stance: Is FDA Commissioner In Limbo?
HHS' interest in the safety of RU-486 does not differ from its interest in the safety of all drug products, HHS Secretary Tommy Thompson maintained during an appearance at the National Press Club April 17.
You may also be interested in...
FDA would be more effective if the Senate were not required to confirm the commissioner post, former Acting Commissioner Michael Friedman, MD, wrote in an editorial for the Dec. 20 issue of Science
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011